|
Back to Home » December 2019 News » Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin®-Based Therapies in NHL |
Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin®-Based Therapies in NHL |
December 04, 2019
OSLO, Norway, Dec. 4, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab satetraxetan) on non-Hodgkin's lymphoma (NHL) cell lines will be presented in a poster at the 61st American...
Source URL: https://www.prnewswire.com:443/news-releases/nordic-nanovector-new-preclinical-data-offer-insights-into-enhancing-betalutin-based-therapies-in-nhl-300968889.html
|
|
|
|
